Cart
sales@molnova.com
RS5517
CAS No. 2227017-46-9
RS5517( —— )
Catalog No. M37024 CAS No. 2227017-46-9
RS5517 is a novel PDZ1 structural domain ligand for the study of colorectal cancer.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 102 | Get Quote |
|
| 5MG | 150 | Get Quote |
|
| 10MG | 221 | Get Quote |
|
| 25MG | 361 | Get Quote |
|
| 50MG | 533 | Get Quote |
|
| 100MG | 761 | Get Quote |
|
| 500MG | 2358 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameRS5517
-
NoteResearch use only, not for human use.
-
Brief DescriptionRS5517 is a novel PDZ1 structural domain ligand for the study of colorectal cancer.
-
DescriptionRS5517 is a specific PDZ1-domain antagonist of NHERF1 that prevented its ectopic nuclear entry. RS5517 can be used for the research of colorectal cancer.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2227017-46-9
-
Formula Weight390.86
-
Molecular FormulaC23H19ClN2O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C(NC1=CC=C(C=C1)CO)C=2NC=3C=CC(Cl)=CC3C2CC=4C=CC=CC4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Saponaro C, et al. β-catenin knockdown promotes NHERF1-mediated survival of colorectal cancer cells: implications for a double-targeted therapy. Oncogene. 2018 Jun;37(24):3301-3316. doi: 10.1038/s41388-018-0170-y. Epub 2018 Mar 19.
molnova catalog
related products
-
Rhamnocitrin 3-gluco...
Rhamnocitrin 3-glucoside is a natural product for research related to life sciences.
-
Filorexant
Filorexant is an orally bioavailable effective and selective reversible antagonist of OX1 and OX2 receptor with (Ki <3 nM).
-
Oxindole
Oxindole is an aromatic heterocyclic building block.?2-indolinone derivatives have become lead compounds in the research of kinase inhibitors.Oxindole structure has been used in receptor tyrosine kinases (RTKs) inhibitors such as SU4984 and intedanib, the RTK family represents an important therapeutic target for anti-cancer drug development.
